What changed in this filing

/stocks — the workspaceLOADING

Item 5. Market for Registrant’s Common Equity

2025-06-30 compared with 2024-07-01 · 27 added, 52 removed, 7 unchanged (92% of the section changed)

Market for Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

common stock is quoted on the OTCQB under the symbol “SUND.” There is no “established

trading market” for our shares of common stock.

No assurance can be given that any established trading market for our common stock

will develop or be maintained, and if an established trading market develops in the future, the sale of shares of our common stock that

are deemed to be “restricted securities” or “control securities” pursuant to Rule 144 of the SEC by members of

management or others may have a substantial adverse impact on any such market.

had 102 stockholders of record as of July 1, 2024 and an indeterminate number of stockholders who hold shares in “street name”.

common stock is quoted on the OTCQB under the symbol “SUND.” There is no “established trading market” for our

shares of common stock.

No assurance can be given that any established trading market for our common stock will develop or be maintained,

and if an established trading market develops in the future, the sale of shares of our common stock that are deemed to be “restricted

securities” or “control securities” pursuant to Rule 144 of the SEC by members of management or others may have a substantial

adverse impact on any such market.

of June 29, 2025, we had 128 stockholders of record and an indeterminate number of stockholders who held shares in “street name.”

are no present material restrictions that limit our ability to pay dividends on our common or preferred stock.

Presently, we have no

plans to pay any dividends in the foreseeable future.

Our Board of Directors intends to pursue a policy of retaining earnings, if any,

for use in our operations and to finance expansion of our business.

plans to pay dividends in the foreseeable future.

Our Board of Directors intends to pursue a policy of retaining earnings, if any, for

use in our operations and to finance the expansion of our business.

Any declaration and payment of dividends in the future, of which

there can be no assurance, will be determined by our Board of Directors in light of conditions then existing, including our earnings,

financial condition, capital requirements and other factors.

There are presently no dividends which are accrued or owing with respect

to our outstanding common stock.

there can be no assurance, will be determined by our Board of Directors in light of existing conditions, including our earnings, financial

condition, capital requirements and other factors.

There are presently no dividends which are accrued or owing with respect to our outstanding

common stock.

No assurance can be given that dividends will ever be declared or paid on our common stock in the future.

Sales of Unregistered Securities

the year ended March 31, 2023 the Company issued 264,600 warrants to the Chairman of the Board of Directors and 120,000 warrants to Radiant

Life, LLC in conjunction with monies borrowed during the period (see Note 8).

The exercise price of these warrants was $1.05.

of the warrants on the date of grant, as calculated by the Black-Scholes-Merton valuation model was $365,502.

The inputs used in this

calculation included a fair value of the underlying common stock of $1.049 per share, a risk-free between 3.62% and 4.31%, volatility

between 142.23% and 148.56% and a dividend rate of 0%.

the year ended March 31, 2023, the Company issued 339,749 warrants to Mr.

Dickman, 719,300 warrants to the Chairman of the Board of Directors,

and 649,754 warrants to Radiant Life, LLC in conjunction with an extension of the maturity dates during the period (see Note 8) per the

terms outlined above.

The exercise price of these warrants was $1.05.

The value of the warrants on the date of grant, as calculated by

the Black-Scholes-Merton valuation model was $1,678,810.

The inputs used in this calculation included a fair value of the underlying

common stock of $1.049 per share, a risk-free between 3.49% and 3.95%, volatility between 142.92% and 145.49% and a dividend rate of

August 15, 2023, we issued a private placement memorandum offering to raise up to $1,500,000 through the issuance of restricted shares

of our common stock (par value $0.001) to qualified investors.

From September 20, 2023 to October 4, 2023, we received subscription agreements

from investors, for 850,000 common shares at a purchase price of $1 per share, including 1,700,000 warrants exercisable at $0.35 per

share, vested immediately upon issuance, with a five year expiration.

Proceeds to us totaled $850,000.

the year ended March 31, 2024 the Company issued 281,900 warrants to the Chairman of the Board of Directors and 80,000 warrants to Radiant

Life, LLC in conjunction with monies borrowed during the period (see Note 8 to the financial statements included in this report).

The exercise price of these warrants was $1.05.

of the warrants on the date of grant, as calculated by the Black-Scholes-Merton valuation model was $316,756.

The inputs used in this

calculation included a fair value of the underlying common stock of $1.049 per share, a risk-free between 3.36% and 4.29%, volatility

between 86.52% and 89.11% and a dividend rate of 0%.

the year ended March 31, 2024, the Company issued 1,106,000 warrants to Mr.

Dickman, 772,275 warrants to the Chairman of the Board of

Directors, and 699,754 warrants to Radiant Life, LLC in conjunction with an extension of the maturity dates during the period (see Note 8 to the financial statements included in this report) per the terms outlined above.

The exercise price of these warrants was between $0.41 and $1.05.

The value of the warrants on the date

of grant, as calculated by the Black-Scholes-Merton valuation model was $964,277.

The inputs used in this calculation included a fair

value of the underlying common stock between $0.409 and $1.049 per share, a risk-free between 3.80% and 4.01%, volatility between 84.00%

and 89.07% and a dividend rate of 0%.

the year ended March 31, 2025, the Company issued 1,544,550 warrants to the Chairman of the Board of Directors in conjunction with an

extension of the maturity dates of certain debt instruments.

The exercise price of these warrants was $0.41 per share.

The value of the

warrants on the date of grant, as calculated by the Black-Scholes-Merton valuation model was $435,199.

The valuation inputs included

a fair value of the underlying common stock of $0.409 per share, a risk-free interest rate of 4.43%, an expected volatility of 83.74%

and a dividend yield of of 0%.

June 18, 2024, to July 10, 2024, the Company received subscription agreements from investors, for 805,000 common shares at a purchase

price of $1 per share, including 1,610,000 warrants exercisable at $0.35 per share, vested immediately upon issuance, with a five year

Proceeds to the company totaled $805,000.

securities were issued in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act and Rule 506

of Regulation D.

of Equity Securities by Us and Affiliated Purchasers

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 5. Market for Registrant’s Common Equity